Literature DB >> 31323628

Muenke syndrome: long-term outcome of a syndrome-specific treatment protocol.

Bianca K den Ottelander1, Robbin de Goederen1, Marie-Lise C van Veelen2, Stephanie D C van de Beeten1, Maarten H Lequin3, Marjolein H G Dremmen4, Sjoukje E Loudon5, Marieke A J Telleman5, Henriëtte H W de Gier6, Eppo B Wolvius7, Stephen T H Tjoa7, Sarah L Versnel1, Koen F M Joosten8, Irene M J Mathijssen1.   

Abstract

OBJECTIVE: The authors evaluated the long-term outcome of their treatment protocol for Muenke syndrome, which includes a single craniofacial procedure.
METHODS: This was a prospective observational cohort study of Muenke syndrome patients who underwent surgery for craniosynostosis within the first year of life. Symptoms and determinants of intracranial hypertension were evaluated by longitudinal monitoring of the presence of papilledema (fundoscopy), obstructive sleep apnea (OSA; with polysomnography), cerebellar tonsillar herniation (MRI studies), ventricular size (MRI and CT studies), and skull growth (occipital frontal head circumference [OFC]). Other evaluated factors included hearing, speech, and ophthalmological outcomes.
RESULTS: The study included 38 patients; 36 patients underwent fronto-supraorbital advancement. The median age at last follow-up was 13.2 years (range 1.3-24.4 years). Three patients had papilledema, which was related to ophthalmological disorders in 2 patients. Three patients had mild OSA. Three patients had a Chiari I malformation, and tonsillar descent < 5 mm was present in 6 patients. Tonsillar position was unrelated to papilledema, ventricular size, or restricted skull growth. Ten patients had ventriculomegaly, and the OFC growth curve deflected in 3 patients. Twenty-two patients had hearing loss. Refraction anomalies were diagnosed in 14/15 patients measured at ≥ 8 years of age.
CONCLUSIONS: Patients with Muenke syndrome treated with a single fronto-supraorbital advancement in their first year of life rarely develop signs of intracranial hypertension, in accordance with the very low prevalence of its causative factors (OSA, hydrocephalus, and restricted skull growth). This illustrates that there is no need for a routine second craniofacial procedure. Patient follow-up should focus on visual assessment and speech and hearing outcomes.

Entities:  

Keywords:  D = diopters; FOA = fronto-supraorbital advancement; FOHR = frontal occipital horn ratio; ICH = intracranial hypertension; ICP = intracranial pressure; Muenke syndrome; OAE = otoacoustic emission; OCT = optical coherence tomography; OE = occipital expansion; OFC = occipital frontal head circumference; OSA = obstructive sleep apnea; TH = tonsillar herniation; TRT = total retinal thickness; craniofacial; craniosynostosis; intracranial hypertension; oAHI = obstructive apnea–hypopnea index

Year:  2019        PMID: 31323628     DOI: 10.3171/2019.5.PEDS1969

Source DB:  PubMed          Journal:  J Neurosurg Pediatr        ISSN: 1933-0707            Impact factor:   2.375


  3 in total

1.  Cervical Spinal Cord Compression and Sleep-Disordered Breathing in Syndromic Craniosynostosis.

Authors:  B K den Ottelander; R de Goederen; C A de Planque; S J Baart; M L C van Veelen; L J A Corel; K F M Joosten; I M J Mathijssen; M H G Dremmen
Journal:  AJNR Am J Neuroradiol       Date:  2020-12-03       Impact factor: 3.825

2.  Saethre-Chotzen syndrome: long-term outcome of a syndrome-specific management protocol.

Authors:  Bianca K Den Ottelander; Marie-Lise C Van Veelen; Robbin De Goederen; Stephanie Dc Van De Beeten; Marjolein Hg Dremmen; Sjoukje E Loudon; Sarah L Versnel; Ans Mw Van Den Ouweland; Marieke F Van Dooren; Koen Fm Joosten; Irene Mj Mathijssen
Journal:  Dev Med Child Neurol       Date:  2020-09-09       Impact factor: 5.449

Review 3.  Prevalence of Ocular Anomalies in Craniosynostosis: A Systematic Review and Meta-Analysis.

Authors:  Parinaz Rostamzad; Zehra F Arslan; Irene M J Mathijssen; Maarten J Koudstaal; Mieke M Pleumeekers; Sarah L Versnel; Sjoukje E Loudon
Journal:  J Clin Med       Date:  2022-02-18       Impact factor: 4.241

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.